{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:17:28Z","timestamp":1783189048874,"version":"3.54.6"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.diagmicrobio.2019.114925","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T11:35:48Z","timestamp":1573817748000},"page":"114925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)"],"prefix":"10.1016","volume":"96","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna M.","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0005","unstructured":"European Surveillance of Antimicrobial Consumption Network (ESAC-Net). https:\/\/ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/esac-net. 2017."},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.idc.2016.02.003","article-title":"The continuing plague of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae infections","volume":"30","author":"Adler","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","article-title":"Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients","volume":"57","author":"Armand-Lefevre","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0020","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0030","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Available from:http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/arthreats-2013-508.pdf. 2013."},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/mdr.2015.0220","article-title":"Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice","volume":"22","author":"Cerceo","year":"2016","journal-title":"and emerging treatment options Microb Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/1060028017748943","article-title":"Is it time to rethink the notion of carbapenem-sparing therapy against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae bloodstream infections? A critical review","volume":"52","author":"Chastain","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.meegid.2018.04.005","article-title":"Current epidemiology, genetic evolution and clinical impact of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"61","author":"Chong","year":"2018","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0050","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","volume":"M07","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0055","series-title":"Performance standards for antimicrobial susceptibility testing","volume":"M100","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0060","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.2016.1154538","article-title":"Treatment options for extended-spectrum \u03b2-lactamase (ESBL) and AmpC-producing bacteria","volume":"17","author":"D'Angelo","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2019.114925_bb0065","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/jtm\/taw102","article-title":"The ecology of extended-spectrum \u03b2-lactamases (ESBLs) in the developed world","volume":"24","author":"Doi","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0070","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0, 2019 (valid from 1 January 2019)."},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0075","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dku025","article-title":"Ceftazidime\/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)","volume":"69","author":"Flamm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2014.07.005","article-title":"Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)","volume":"80","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1473-3099(14)70950-8","article-title":"\u03b2-lactam and \u03b2-lactamase inhibitor combinations in the treatment of extended-spectrum \u03b2-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?","volume":"15","author":"Harris","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0100","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200442","article-title":"Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST 131) H30 and H30Rx status","volume":"13","author":"Johnston","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0110","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0115","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0120","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","author":"Karlowsky","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0125","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0130","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jgar.2015.05.005","article-title":"Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013","volume":"3","author":"Lob","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0140","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2018.05.017","article-title":"Activity of imipenem-relebactam against gram-negative bacilli from global ICU and non-ICU wards-SMART 2015-2016","volume":"15","author":"Lob","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0150","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/AAC.04498-14","article-title":"In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-\u03b2-lactamase-harboring Enterobacteriaceae","volume":"59","author":"Melchers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx099","article-title":"Comparison between carbapenems and \u03b2-lactam\/\u03b2-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"4","author":"Muhammed","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0165","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkt450","article-title":"Determining a clinical framework for use of cefepime and \u03b2-lactam\/\u03b2-lactamase inhibitors in the treatment of infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"69","author":"Nguyen","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0175","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum \u03b2-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0180","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0185","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgar.2017.05.025","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013-2015)","volume":"10","author":"Pfaller","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0200","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0210","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1128\/AAC.00405-16","article-title":"Antimicrobial activities of ceftazidime-avibactam and comparator agents against gram-negative organisms isolated from patients with urinary tract infections in U.S. medical centers, 2012 to 2014","volume":"60","author":"Sader","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00533-18","article-title":"In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0225","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0230","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0235","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0240","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0245","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.114925_bb0255","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.clinthera.2016.04.035","article-title":"Pathogen prevalence and antimicrobial susceptibility among Enterobacteriaceae causing hospital associated intra-abdominal infections in adults in the United States (2012-2013)","volume":"38","author":"Zalacain","year":"2016","journal-title":"Clin Therapeutics"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319307461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319307461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:50Z","timestamp":1760003570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319307461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0732889319307461"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114925","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114925"}}